Paperonium

Blood cancer · J Clin Oncol · 2024

“High-risk test results predict full myeloma.” But the summary’s best guess falls outside its own range.

The summaryfalls outside its own rangeThe results sectionsits inside its range0.12×0.14 to 1.13should be inside0.10×0.010.960.01×0.03×0.1×0.3×1×no difference
The summaryfalls outside itsown rangeThe results sectionsits inside its range0.12×0.14 to 1.13should be inside0.10×0.010.960.01×0.1×1×no difference

Times as likely to progress without the high-risk results

The paper says

Among 90 people with early-stage myeloma, a blood cancer, the summary says certain high-risk test results predicted who progressed to full myeloma. Its best guess: people without them were 0.12 times as likely to progress, with a range of 0.14 to 1.13 times.

Its own data show

0.12 lies below its own range, and rounding can’t explain that. The range also includes 1 (equally likely), so it can’t rule out “no difference”. The results section gives a version that fits: 0.10 times, range 0.01 to 0.96. Its counts: 4 of 28 with the high-risk results progressed (14%), 1 of 62 without (1.6%).

A study reports a best guess and a range around it, the values its data can’t rule out, so the guess must lie inside. The summary, the part most readers see, can’t be right as printed. The version that fits rests on just 5 cases of full myeloma: thin support for calling these results the only predictor.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance · J Clin Oncol (2024) · doi:10.1200/JCO.23.02771